 |
|
|
January 13, 2009
Torii Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. |
|
|
Torii Pharmaceutical to Solely Market Antiemetic Drugs
"Serotone® I.V. Injection 10 mg" and "Serotone® Tablets 10 mg" |
|
It was announced today that Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo, hereinafter referred to as "Torii") would become the sole marketer and distributor of 5-HT3 receptor antagonists (antiemetics) "Serotone® I.V. Injection 10 mg" and "Serotone® Tablets 10 mg" and exclusively handle its promotion activities from April 2009 accordingly.
These 5-HT3 receptor antagonists (antiemetics), "Serotone® Intravenous Injection 10 mg" (generic name: azasetron hydrochloride injection) and "Serotone® Tablets 10 mg" (generic name: azasetron hydrochloride tablet) have been co-marketed by Torii and Taiho Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Toru Usami, hereinafter referred to as "Taiho"). Torii alone will market these drugs from April 2009 as Taiho will terminate sales on March 31, 2009.
The 5-HT3 receptor antagonists, "Serotone® I.V. Injection 10 mg" and "Serotone® Tablets 10 mg," were antiemetics jointly developed by Yoshitomi Pharmaceutical Industries, Ltd. (currently Mitsubishi Tanabe Pharma Corporation) and Japan Tobacco Inc. and the manufacturing and marketing approval was obtained by Japan Tobacco Inc.
| |
|
| [ About: Outline of Serotone® I.V. Injection 10 mg and Serotone® Tablets 10 mg ] |
|
| |
Serotone® I.V. Injection 10 mg |
Serotone® Tablets 10 mg |
Active ingredient
and content |
Azasetron hydrochloride 10 mg |
| Indication |
Nausea and vomiting caused by cancer chemotherapy (such as cisplatin chemotherapy) |
| Dosage and administration |
The recommended adult dosage is 10 mg of azasetron hydrochloride, administered intravenously once daily. If the efficacy is not sufficient, the same dose of azasetron hydrochloride may be additionally administered. The total daily dosage should not exceed 20 mg. |
The recommended adult dosage is 10 mg of azasetron hydrochloride, administered orally once daily. The dose may be appropriately adjusted, according to patient age and symptoms. The total daily dosage should not exceed 15 mg. |
| Packaging |
Five 2-mL vials |
10 tablets (10 tablets×1 sheet; press-through package) |
| Launch date |
December 2007
Note) Launched in April 1994 under the name of Serotone® Injection |
October 1999 |
| NHI (reimbursement) price |
2-mL vial containing 10 mg: 6,107.00 Japanese Yen |
Tablet containing 10 mg: 1,582.20 Japanese Yen |
| Manufacturer/ distributor |
Japan Tobacco Inc. |
|
|
|
|
|
| |
|
|
|
|
